Brazil sets out strategy for control dengue in 2003
This article was originally published in Clinica
The Brazilian health ministry has set out ambitious goals for its R$1bn (US$331m) dengue control programme (PNCD) in 2003. At a meeting in Brasilia last week, the newly-created PNCD committee announced a target of halving this year's incidence of the disease, and of reducing to 1% the death rate associated with the haemorrhagic form of the condition. Early diagnosis is the key to controlling the disease in its milder form, following infection from one serotype, prior to its progression to the haemorrhagic form, through exposure to a different serotype (see Clinica No 1001, p 14).
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.